[1]
D. Maji and S. Samanta, “A REVIEW ON THE ROLE OF PPARγ AGONISTS AND HYBRIDS IN TYPE 2 DIABETES AND CARDIOMYOPATHY”., Asian J Pharm Clin Res, vol. 8, no. 2, pp. 26–31, Mar. 2015.